Sangamo Therapeutics (SGMOQ) Cash from Investing Activities (2010 - 2025)

Sangamo Therapeutics has reported Cash from Investing Activities for 16 years, with the latest figure at -$14000.0 in Q4 2025.

• On a quarterly basis, Cash from Investing Activities fell 101.06% year-over-year to -$14000.0 in Q4 2025; TTM through Dec 2025 was -$102000.0, a 100.27% decrease from a year earlier, with the FY2025 full-year figure at -$102000.0, down 100.27% from the prior year.
• Cash from Investing Activities was -$14000.0 for Q4 2025 at Sangamo Therapeutics, up from -$64000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $89.3 million in Q2 2021, with the low at -$13.5 million in Q3 2022.
• Average Cash from Investing Activities over 5 years is $26.2 million, with a median of $35.7 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities soared 1995.48% in 2023, then tumbled 127.47% in 2025.
• Over 5 years, Cash from Investing Activities stood at $52.6 million in 2021, then declined by 19.04% to $42.6 million in 2022, then fell by 11.51% to $37.7 million in 2023, then slumped by 96.49% to $1.3 million in 2024, then plunged by 101.06% to -$14000.0 in 2025.
• The last three Cash from Investing Activities figures came in at -$14000.0 (Q4 2025), -$64000.0 (Q3 2025), and -$24000.0 (Q2 2025), per Business Quant data.